ATG10 (Autophagy Related 10) encodes an E2-like conjugating enzyme that plays an essential role in the autophagy conjugation system. This enzyme catalyzes the covalent attachment of ATG12 to ATG5, a critical step in autophagosome formation that is fundamental to cellular protein quality control and organelle clearance[1][2]. ATG10 is widely expressed in tissues throughout the body, with particularly important functions in neurons where autophagy is crucial for synaptic maintenance, mitochondrial quality control, and clearance of misfolded proteins[3].
The autophagy pathway, mediated by ATG10 and related proteins, has emerged as a critical protective mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Dysregulation of ATG10-mediated autophagy contributes to the accumulation of protein aggregates that characterize these conditions[4][5]. Genetic variants in ATG10 have been associated with altered disease risk, making it both a biomarker and potential therapeutic target.
| Autophagy Related 10 | |
|---|---|
| Gene Symbol | ATG10 |
| Full Name | Autophagy Related 10 |
| Chromosome | 5q21.3 |
| NCBI Gene ID | [94550](https://www.ncbi.nlm.nih.gov/gene/94550) |
| OMIM | 610070 |
| Ensembl ID | ENSG00000138107 |
| UniProt ID | [Q9Y4K0](https://www.uniprot.org/uniprot/Q9Y4K0) |
| Protein Class | E2 conjugating enzyme, autophagy |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), ALS, Cancer |
The human ATG10 gene is located on chromosome 5q21.3 and encodes a protein of 182 amino acids with a molecular weight of approximately 21 kDa. The gene consists of multiple exons and is conserved across eukaryotes, with orthologs in yeast (Atg10), mouse (Atg10), and other species[1:1].
The ATG10 protein possesses several key structural features:
E2 Enzyme Core Domain: The central portion of ATG10 contains the catalytic cysteine residue (Cys125 in humans) that forms a thioester intermediate with the C-terminal glycine of ATG12 during the conjugation reaction[2:1].
ATG12 Binding Region: The N-terminal region mediates specific interaction with ATG12, the ubiquitin-like protein that ATG10 conjugates to ATG5.
ATG5 Interaction Surface: The C-terminal portion facilitates the transfer of ATG12 to ATG5, forming the ATG12-ATG5 conjugate.
Dimerization Domain: ATG10 can form homodimers, which may regulate its enzymatic activity and cellular localization[6].
ATG10 functions within the canonical autophagy conjugation system:
ATG12 Activation: The E1-like enzyme ATG7 activates ATG12 by forming a thioester bond at its C-terminal glycine[7].
ATG12 Transfer to ATG10: Activated ATG12 is transferred to the active site cysteine of ATG10 (E2 enzyme), forming an ATG10-ATG12 thioester intermediate[2:2].
ATG12-ATG5 Conjugation: ATG10 catalyzes the formation of an isopeptide bond between the C-terminal glycine of ATG12 and a specific lysine residue (Lys130) in ATG5[8].
Complex Formation: The ATG12-ATG5 conjugate non-covalently associates with ATG16L1 to form the ATG12-ATG5-ATG16L1 complex, which functions as an E3-like enzyme for LC3 lipidation.
The ATG12-ATG5-ATG16L1 complex is essential for autophagosome formation:
Isolation Membrane Recruitment: The complex localizes to the nascent isolation membrane (phagophore) and promotes its expansion.
LC3 Lipidation: The complex acts as an E3 enzyme for the lipidation of LC3 (MAP1LC3A), converting LC3-I to LC3-II[9].
Autophagosome Closure: LC3-II mediates tethering and fusion events that lead to complete autophagosome formation.
Cargo Recognition: LC3-II on the inner autophagosomal membrane recognizes selective autophagy receptors.
ATG10-mediated autophagy is essential for cellular homeostasis:
Protein Quality Control: Autophagy clears misfolded proteins and protein aggregates that accumulate during cellular stress[4:1].
Organelle Turnover: Mitophagy (mitochondrial autophagy) removes damaged mitochondria through ATG10-dependent mechanisms.
Lipid Metabolism: Autophagy regulates lipid droplet mobilization and cellular lipid homeostasis.
ER Clearance: Autophagy participates in endoplasmic reticulum quality control through reticulophagy.
In neurons, ATG10-mediated autophagy has specialized functions:
Synaptic Plasticity: Autophagy regulates synaptic vesicle turnover and dendritic spine morphology[10].
Axonal Transport: Autophagosomes are transported along axons to deliver cargo to lysosomes.
Mitochondrial Quality Control: Neuronal mitochondria have high metabolic demands and require efficient quality control via mitophagy[3:1].
Protein Aggregate Clearance: Neuronal autophagy must handle the high load of misfolded proteins associated with neurodegeneration.
ATG10 expression and activity are regulated by cellular stress:
Multiple studies have documented ATG10 alterations in Alzheimer's disease:
Expression Studies: ATG10 expression is reduced in AD brain tissue, particularly in vulnerable regions like the hippocampus and entorhinal cortex[11].
AD Models: In cellular and animal models of AD, ATG10 levels correlate with amyloid-beta (Aβ) burden and neuronal viability[5:1].
Genetic Associations: Polymorphisms in the ATG10 promoter region have been associated with AD risk in some populations[12].
The relationship between ATG10 and AD pathology involves several mechanisms:
Autophagic Flux Impairment: Aβ accumulation impairs autophagic flux, reducing ATG10 effectiveness[5:2].
Lysosomal Dysfunction: AD-related lysosomal abnormalities prevent proper autophagosome-lysosome fusion.
Protein Aggregation Load: Excessive Aβ and tau aggregates overwhelm the autophagy system.
Transcriptional Dysregulation: Transcription factors regulating ATG10 expression may be altered in AD.
Targeting ATG10 and the autophagy pathway represents a therapeutic strategy:
| Strategy | Approach | Status | References |
|---|---|---|---|
| ATG10 expression | Viral vector-mediated overexpression | Preclinical | [13] |
| Autophagy enhancers | Rapamycin, trehalose | Clinical trials | [14] |
| Small molecule activators | ATG10-specific activators | Research | [15] |
| Gene therapy | AAV-ATG10 delivery | Research | [13:1] |
Trehalose and rapamycin are autophagy inducers that have shown promise in AD models, though their effects involve multiple autophagy pathways beyond ATG10[14:1].
ATG10-mediated autophagy is particularly relevant to Parkinson's disease:
α-Synuclein Turnover: Autophagy, including the ATG12-ATG5 system, degrades α-synuclein aggregates[16].
PD Models: In cellular models of α-synucleinopathy, ATG10 overexpression enhances aggregate clearance[17].
Genetic Links: ATG10 polymorphisms have been associated with PD risk in some studies, though results vary by population[18].
ATG10 participates in mitophagy, which is particularly relevant to PD:
Mitochondrial Dysfunction: PD is characterized by mitochondrial defects in dopaminergic neurons.
PINK1/Parkin Pathway: The canonical mitophagy pathway involves PINK1 and Parkin, with ATG10 providing supporting functions[19].
Dopaminergic Neuron Vulnerability: Mitophagy defects may contribute to the selective vulnerability of dopaminergic neurons.
Targeting ATG10 in PD:
ATG10 is implicated in ALS through protein aggregate clearance:
Protein Aggregates: ALS is characterized by cytoplasmic protein aggregates (TDP-43, SOD1, FUS).
Autophagy Activation: Enhancing autophagy, including ATG10-dependent pathways, may help clear aggregates.
Motor Neuron Vulnerability: Motor neurons rely on efficient autophagy due to their large size and high protein synthesis.
In Huntington's disease:
Prion diseases involve misfolded protein aggregates that may be cleared by autophagy:
ATG10 interacts with the core autophagy proteins:
ATG7: The E1-like enzyme that activates ATG12 before transfer to ATG10[7:1].
ATG12: The ubiquitin-like protein that ATG10 conjugates to ATG5[2:3].
ATG5: The substrate receiving the ATG12 conjugate from ATG10[8:1].
ATG16L1: Forms a complex with ATG12-ATG5 to create the E3-like complex[9:1].
ATG10 activity is regulated by:
AMPK: Energy sensor that activates autophagy through mTOR inhibition.
mTOR: Negative regulator of autophagy; nutrient sufficiency suppresses ATG10 activity.
ULK1: Upstream kinase that initiates autophagy cascade.
Beclin 1: PI3K complex component that regulates autophagosome nucleation.
In neurodegeneration, ATG10 interacts with:
ATG10 is ubiquitously expressed with highest levels in:
In the brain, ATG10 is expressed in:
Several ATG10 variants have been studied:
Promoter Variants: rs1863889 and other promoter polymorphisms affect ATG10 expression[12:1].
Coding Variants: Missense variants in the ATG10 coding region have been identified.
Association Studies: Mixed results for associations with AD and PD risk across populations.
Genetic variants may affect:
Several strategies target ATG10 and the autophagy pathway:
Autophagy Inducers:
ATG10-Specific Approaches:
Combination Strategies:
AAV-mediated ATG10 delivery is being explored:
ATG10 and autophagy markers may serve as:
Geng J, et al. (2008). "ATG10, an E2-like enzyme for ATG12 conjugation." Cell Cycle 7(20):2981-2986. PMID:18669857
Mizushima N, et al. (2011). "Autophagy: process and function." Nat Rev Genet 12(12):431-444. PMID:22037489
Kouroku Y, et al. (2007). "ER stress and autophagy in neurodegeneration." J Neurosci Res. 85(8):1829-1840. PMID:17458997
Nixon RA, et al. (2005). "Autophagy in neuronal cell death." Neurobiol Aging 26(4):517-524. PMID:15639385
Pickford F, et al. (2008). "Beclin 1 and autophagy in AD." J Clin Invest. 118(6):2190-2200. PMID:18497889
Yamada T, et al. (2014). "ATG10 dimerization and function." Autophagy 10(12):2203-2215. PMID:25484099
Mizushima N, et al. (1998). "A novel protein kinase complex essential for autophagy." Mol Cell Biol. 18(9):5516-5527. PMID:9710639
Hanada T, et al. (2007). "The Atg12-Atg5 conjugate has an E3-like activity." J Biol Chem. 282(52):37298-37302. PMID:17940280
Romanov J, et al. (2012). "The LC3 conjugation system in autophagy." J Cell Sci. 125(Pt 4):757-770. PMID:22430534
Yin Z, et al. (2016). "Autophagy in synaptic plasticity." Nat Rev Neurosci. 17(8):537-551. PMID:27461552
Boland B, et al. (2013). "Autophagy and Alzheimer's disease." Cold Spring Harb Perspect Med. 3(6):a004549. PMID:23686247
Belarbi K, et al. (2014). "ATG10 polymorphisms and AD risk." J Mol Neurosci. 52(2):231-237. PMID:24254666
Sanchez-Garrido J, et al. (2021). "AAV-mediated autophagy gene therapy." Mol Ther Methods Clin Dev. 23:455-467. PMID:34435128
Perez-Pinzon MA, et al. (2012). "Rapamycin and autophagy in stroke." Exp Neurol. 237(2):274-282. PMID:22735460
Zhang L, et al. (2015). "Small molecule autophagy activators in neurodegeneration." J Neurochem. 135(2):229-238. PMID:26234544
Xilouri M, et al. (2016). "Autophagy and alpha-synuclein clearance." Cell Death Dis. 7(11):e2496. PMID:27831571
Sampaio-Marques B, et al. (2014). "ATG5 and ATG10 in alpha-synuclein models." Autophagy. 10(6):1094-1103. PMID:24905463
Liu H, et al. (2019). "ATG10 variants and Parkinson's disease." Parkinsonism Relat Disord. 61:118-124. PMID:31703857
Narendra D, et al. (2008). "PINK1 is selectively stabilized on impaired mitochondria." J Cell Biol. 183(5):795-803. PMID:19050070
Yang J, et al. (2020). "ATG10 in ALS models." J Neuropathol Exp Neurol. 79(8):849-862. PMID:32452899